EDP-305

• Description:

  EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells) . EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research[1][2].

• UNSPSC:

  12352005

• Target:

  Cytochrome P450; FXR; Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/edp-305.html

• Purity:

  96.02

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O[C@H]1[C@]2([H])[C@@](CC[C@]3([C@@]2([H])CC[C@]3([H])[C@H](C)CCNC(NS(=O)(C4=CC=C(C=C4)C(C)(C)C)=O)=O)C)([H])[C@@]5([C@](C[C@@H](CC5)O)([H])[C@H]1CC)C

• Molecular Formula:

  C36H58N2O5S

• Molecular Weight:

  630.92

• References & Citations:

  [1]Erstad DJ, et al. Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. Hepatol Commun. 2018 May 21;2 (7) :821-835. |[2]Chau M, et al. Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis[J]. International Journal of Gastroenterology, 2019 (1) .

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [1933507-63-1]